Cargando…
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
BACKGROUND: To compare the periodical incidence rates of genitourinary (GU) and gastrointestinal (GI) toxicity in patients who underwent prostate low-dose-rate brachytherapy between the monotherapy group (seed implantation alone) and the boost group (in combination with external beam radiation thera...
Autores principales: | Tanaka, Nobumichi, Asakawa, Isao, Anai, Satoshi, Hirayama, Akihide, Hasegawa, Masatoshi, Konishi, Noboru, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570431/ https://www.ncbi.nlm.nih.gov/pubmed/23363647 http://dx.doi.org/10.1186/1748-717X-8-25 |
Ejemplares similares
-
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012) -
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014) -
The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions
por: Tanaka, Nobumichi, et al.
Publicado: (2014) -
Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report
por: Hori, Shunta, et al.
Publicado: (2014) -
Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2017)